Key Points

  • Harpoon Therapeutics secures a significant $150 million through a PIPE financing.
  • Leading biotechnology investors and a coalition of new and existing supporters contribute.
  • Harpoon offers a combination of 17.17 million shares of common stock and accompanying warrants.
  • The funds are earmarked for clinical development programs and general corporate needs.
  • The financing ensures financial stability and a sustainable operating plan until 2026.

Immunotherapy is at the forefront of medical innovation, promising novel approaches to treating diseases. One company, Harpoon Therapeutics, Inc. (traded as HARP), recently made a significant announcement that reflects the growing interest in this field.

Harpoon Therapeutics revealed that it has entered into a securities purchase agreement for a private placement in public equity (PIPE) financing. This move is anticipated to result in upfront gross proceeds of approximately $100 million, with the potential for an additional approximately $50 million in gross proceeds upon cash exercise of warrants. It's a significant financial infusion that can propel the company's research and development efforts in the domain of immunotherapy.

The PIPE Financing in Detail

Harpoon Therapeutics' PIPE financing is a notable event in the world of biotechnology investments. It was led by a prominent biotechnology investor associated with one of the largest alternative asset managers. The participation included both new and existing investors, creating a coalition of support for the company. Notable contributors to this financing included Soleus Capital, Commodore Capital, New Leaf Venture Partners, Cormorant Asset Management, RA Capital Management, Invus, Surveyor Capital (a Citadel company), K2 HealthVentures, Ally Bridge Group, Lion Point Capital, and a large mutual fund.

The terms of the securities purchase agreement outline the specifics of this financing. At the closing of the deal, Harpoon Therapeutics will issue an aggregate of 17.17 million shares of its common stock. Alongside these shares, the company will offer warrants that allow the purchase of up to an aggregate of 8.58 million shares of its common stock. The pricing for this combined offering is set at $5.8345 per share and its accompanying warrant.

One of the key features of these warrants is that they are exercisable in cash. They have a three-year exercise period following the date of issuance. This financing is on track to conclude around October 25, 2023, pending the fulfillment of customary closing conditions.

Utilization of Proceeds and Future Prospects

The capital raised through this PIPE financing is earmarked for various critical purposes. Firstly, Harpoon Therapeutics intends to channel these funds into supporting its clinical development programs across its platforms. This includes both ongoing clinical studies and future late-stage clinical investigations, particularly in relation to HPN328.

Moreover, a portion of the proceeds will serve as working capital, which is essential for sustaining the company's day-to-day operations. The remainder will be allocated to other general corporate purposes, providing flexibility in addressing emerging needs and opportunities.

A noteworthy aspect of this financing is its potential to secure Harpoon Therapeutics' long-term viability. When combined with the company's existing cash and cash equivalents, the aggregate proceeds are expected to support the current operating plan until 2026. This financial stability is crucial for a biotechnology firm like Harpoon as it allows for sustained research, development, and innovation in the rapidly evolving field of immunotherapy.

In the context of healthcare and biotechnology, financial investments like this PIPE financing can significantly impact the trajectory of research and development. They enable companies like Harpoon Therapeutics to explore new treatments, enhance their clinical programs, and ultimately contribute to the advancement of medical science.

With the future of healthcare promising groundbreaking therapies through immunotherapy and related fields, the support from investors and the success of financing initiatives like this one are vital for bringing these innovations to patients in need.

Disclaimer: The information in this article does not constitute investment advice, endorsement, or a recommendation for any specific company or financial product. Readers are encouraged to conduct their research and consult with financial experts before making investment decisions.



About Harpoon Therapeutics, Inc.


  • Ticker HARP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,106,800
  • Description
  • Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...
More about HARP